Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 736 | BioNTech SEINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT07465133 | Updating the EORTC Quality-of-Life Questionnaire for Ovarian Cancer (QLQ-OV38)(EORTC QLQ-OV39) | not yet recruiting | — | 50 | Helios University Hospital WuppertalOTHER | 1 | Sep 18, 2026 |
| clinicaltrials |
| NCT07497919 | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07548164 | Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer | recruiting | Phase 3 | 224 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07650240 | Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial(SPARKLE) | recruiting | Phase 2 | 202 | Mayo ClinicOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT05003752 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer(Hypo-Combi) | active not recruiting | Phase 1 / Phase 2 | 40 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05011188 | FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Rahul AggarwalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05011383 | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers(VA-BAT) | recruiting | Phase 2 | 51 | VA Office of Research and DevelopmentFED | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05155046 | 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05316129 | Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | recruiting | Phase 1 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05475171 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05616650 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05665738 | Two-fraction HDR Monotherapy for Localized Prostate Cancer | recruiting | N/A | 17 | University of California, San FranciscoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05705921 | Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer | active not recruiting | N/A | 484 | The Netherlands Cancer InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05758688 | PROton Therapy for Post Surgical Treatment of GYNecologic Cancer(PROPS GYN) | recruiting | Phase 2 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01) | recruiting | Phase 3 | 480 | BioNTech SEINDUSTRY | 26 | Sep 17, 2026 | clinicaltrials |
| NCT06568094 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06582446 | Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)(HypoElect) | recruiting | Phase 2 | 30 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06708351 | Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial | not yet recruiting | N/A | 2,280 | Emory UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | recruiting | Phase 3 | 1,440 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 17, 2026 | clinicaltrials |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)(TroFuse-033) | recruiting | Phase 3 | 1,123 | Merck Sharp & Dohme LLCINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)(TroFuse-021) | recruiting | Phase 3 | 900 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07666217 | CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy(CoSMAP) | active not recruiting | — | 625 | Intuitive SurgicalINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07691697 | PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer(PSMA-OLIGO-PRO) | recruiting | — | 1,000 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07813637 | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC(PSMA-013-001) | recruiting | Phase 1 | 110 | Janux TherapeuticsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07818850 | Vagina-View Safety and Imaging Feasibility(Vagina-View) | recruiting | N/A | 10 | University Health Network, TorontoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825181 | Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy(HRD-Italy) | not yet recruiting | — | 1,125 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826858 | SPECTRA: Intraoperative Hyperspectral Imaging for Prostate Cancer(SPECTRA) | recruiting | N/A | 26 | Massimo ValerioOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01834001 | Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy | recruiting | — | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02194387 | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | active not recruiting | N/A | 337 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04604613 | Prediction of Recurrence Among Low Risk Endometrial Cancer Patients | active not recruiting | — | 518 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05677048 | Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | active not recruiting | N/A | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06080113 | Cancer of the Prostate Treated With Focal Implantation of a RadioactivE Source(CAPFIRE) | enrolling by invitation | N/A | 50 | Herlev HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06380738 | Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)(PROceed) | active not recruiting | — | 111 | AstraZenecaINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06409052 | Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women | recruiting | — | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07116213 | Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer | recruiting | N/A | 20 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07549256 | Cannabidiol for Pain Relief of Patients With End-stage mCRPC(ProCan) | recruiting | Phase 2 | 58 | Regionshospital NordjyllandOTHER_GOV | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07584161 | MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer(ARTISAN) | recruiting | N/A | 228 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07608718 | Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 2 | 19 | Pedro Barata, MD, MScOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | recruiting | Phase 2 | 50 | Tufts Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07821879 | Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer(SHALLOW ROUTE) | recruiting | — | 50 | Institut Claudius RegaudOTHER | 1 | Sep 16, 2026 | clinicaltrials |
Data updated 13 days agoSource updated Sep 18, 2026source: clinicaltrials